Community and Hospital‐Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS‐CoV‐2 During the 2023–2024 Season, Lyon, France
Influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 are among the main respiratory viruses circulating in the population, with a significant burden on public health. While individuals at higher risk are more likely to develop severe symptoms leading to hospitalization, viral circulation in the community remains less extensively monitored. This study compared viral circulation between RELAB, a recently established community-based laboratory surveillance network (n = 22 843 tested patients) and hospital surveillance at the Hospices Civils de Lyon, France (n = 23 046 tested patients), for the season 2023-2024. For influenza and SARS-CoV-2, similar trends were observed in at-risk populations (children under 5 years and adults over 65 years) in both settings. Circulation of these two viruses was first detected in the community and insights from the young adult population (19-64 years) were only captured in the community network. Circulation of RSV was more intense in terms of number of cases and started in the pediatric population, and consequently was more represented in the hospital setting. In conclusion, this study highlighted the complementarity between community and hospital surveillance, as different populations and periods of viral circulation were observed.
Authors
- Simon Cauchemez (ORCID: https://orcid.org/0000-0001-9186-4549)
- Alexandre Gaymard (ORCID: https://orcid.org/0000-0002-8194-6126)
- Marta Coelho Nunes (ORCID: https://orcid.org/0000-0003-3788-878X)
- Benoît Visseaux (ORCID: https://orcid.org/0000-0002-9279-5538)
- Jean‐Sébastien Casalegno (ORCID: https://orcid.org/0000-0003-3271-9856)
- Marie‐Anne Rameix‐Welti (ORCID: https://orcid.org/0000-0002-5901-3856)
- Marta Fabre (ORCID: https://orcid.org/0000-0003-4744-0903)
- Florence Morfin (ORCID: https://orcid.org/0000-0002-1962-808X)
- Vincent Enouf (ORCID: https://orcid.org/0000-0001-7609-4742)
- Antonin Bal (ORCID: https://orcid.org/0000-0002-0261-2495)
- Antoine Oblette (ORCID: https://orcid.org/0000-0001-7958-8019)
- Emmanuel Chanard
- Laurence Josset (ORCID: https://orcid.org/0000-0002-7158-1186)
- Jean‐Marc Giannoli
- Vincent Vieillefond
- Cécile Chauvel (ORCID: https://orcid.org/0009-0005-2563-5816)
- Juliette Paireau (ORCID: https://orcid.org/0000-0002-5143-6256)
- Bruno Lina
- Stéphanie Haim‐Boukozba
Institutions
- Université Claude Bernard Lyon 1 (FR)
- École Normale Supérieure de Lyon (FR)
- Saint-Gobain (France) (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Pasteur (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Délégation Rhône Auvergne (FR)
- Santé Publique France (FR)
- Hospices Civils de Lyon (FR)
- Velocity BioGroup (United States) (US)
- Institut Technique de l'Aviculture (FR)
- University of Bío-Bío (CL)
- Centre International de Recherche en Infectiologie (FR)
- Infection et inflammation (FR)
- Virbac (France) (FR)
- LyondellBasell (United States) (US)
Publication Details
- Journal
- Journal of Medical Virology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1002/jmv.70549
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Sanofi
- Hospices Civils de Lyon
- Université Claude Bernard Lyon 1